AstraZeneca Pharma India Ltd. — Earnings Release 2024

May 27, 2024

==> picture [503 x 53] intentionally omitted <==

May 27, 2024

The Manager – Listing BSE Limited 1[st] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 400001

The Manager – Listing National Stock Exchange of India Ltd. Exchange Plaza, 5[th] Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Press Release

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Please find enclosed the press release for the audited financial results for the financial year ended March 31, 2024.

Thanking you,

For AstraZeneca Pharma India Limited

MANASA Digitally signed by MANASA RAMA RAMA Date: 2024.05.27 19:01:30 +05'30' Manasa. R Company Secretary

==> picture [452 x 64] intentionally omitted <==

Press Release

==> picture [96 x 27] intentionally omitted <==

AstraZeneca Pharma India Limited achieves growth of 29% for financial year ended March 31, 2024

Bangalore, May 27, 2024: AstraZeneca Pharma India Ltd., a science-led biopharmaceu�cal company, is pleased to announce robust financial results for the financial year ended March 31, 2024. The Company achieved total revenue of INR 1,330 Cr. registering an impressive 29% growth in revenue.

Financial performance highlights for full year 2023 - 24

• Revenue from Opera�on for financial year 2023-24 stood at INR 1,296 Cr. with substan�al 29% increase.

• Profit Before Tax is INR 220 Cr. registering a commendable 64% growth (PBT before excep�onal items at INR 201 Cr., up by 17% compared to previous financial year).

• Earnings Per Share (EPS) for financial year stood at INR 64.6 demonstra�ng a significant growth of 63%

The Board of Directors, at its meeting dated May 27, 2024, have recommended a final dividend of Rs. 24 per equity share for the financial year 2023-24, subject to approval of shareholders at the Annual General Meeting of the Company.

AstraZeneca India con�nues to advance its mission of transforming the future of healthcare by unlocking the power of science for the benefit of people, society, and the planet. The Company's commitment to innova�on is reflected in its strong pipeline progress, reinforcing its posi�on as a key player in the healthcare industry.

AstraZeneca globally announced its new Bold Ambi�on during the recently held Investor’s Day, se�ng the stage for 2030 to deliver $80 billion in Total Revenue. This will be achieved through significant growth in its exis�ng oncology, biopharmaceu�cals and rare disease por�olio, and by launching an expected 20 new medicines before the end of the decade, achieve industry leading growth and aim to be carbon nega�ve.

Dr. Sanjeev Panchal, Country President and Managing Director, AstraZeneca India, commented, " FY 2023-24 was one of the strongest years for us in the country and we take immense pride in our consistent performance. AstraZeneca India products sales for first �me cross INR 1000 Cr mark, delivering total revenue of almost INR ~1300 Cr. with growth of 29% this year. A successful execu�on of our growth through innova�on strategy is helping us propel our ambi�on to be pioneers in science and lead in specialist disease areas in India. Science is guiding us, and our remarkable pipeline progress with 9 new medicines and indica�on approvals that we received last year, posi�ons us op�mally and we feel mo�vated to bring more innova�ve therapies faster and closer to pa�ents in India.

Our scien�fic progress and great support from different states, peers, and industry stakeholders posi�ons us op�mally to achieve our purpose of leaving no pa�ents behind in the therapy areas we are present in and sustainably con�nue our strive to contribute to people, society, and the planet."

Bhavana Agrawal, Chief Finance Officer, added, "Our strong full year performance is reflec�on of company’s focus on being a specialist organiza�on & strong opera�onal execu�on. This achievement reflects our relentless pursuit of iden�fying and capitalizing on opportuni�es in a dynamic

==> picture [96 x 27] intentionally omitted <==

environment. It underscores our dedica�on to not only achieving financial excellence but doing so in a sustainable and strategic manner."

AstraZeneca India remains commi�ed to driving posi�ve impact through groundbreaking scien�fic advancements and looks forward to contribu�ng to the well-being of communi�es.

Key milestones achieved for full year 2023 - 24:

Marke�ng approvals for new molecules & indica�ons:

• Trastuzumab deruxtecan : dual indication for treatment of HER2 low breast cancer and HER2 positive gastric / gastro-oesophageal cancer

• Andexanet Alfa : for critical bleeding conditions associated with use of novel anticoagulants (Factor Xa inhibitors viz. Apixaban, rivaroxaban)

• Triple combination- budesonide (160 mcg), glycopyrrolate (7.2 mcg), and formoterol fumarate (5 mcg) dihydrate , pressurised inhalation, suspension for the effective maintenance treatment and maintenance to relieve symptoms and prevent exacerbations in adult patients with chronic obstructive pulmonary (COPD) disease

• Palivizumab: preventive therapy for Respiratory Syncytial Virus (RSV)

• Dapagliflozin : additional indication approval for treatment of heart failure in adults

• Tremelimumab in combination with Durvalumab: for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)

• Trastuzumab deruxtecan: for the treatment of select HER‐2 positive breast cancer, subsequently launched in January 2024

• Selumetinib : Entry into rare disease therapy in India for treatment of Neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN)

Strategic collabora�ons with:

• Government of Karnataka , National Health Mission, Health & Family Welfare Services, to deploy Qure.ai's Artificial Intelligence (AI) based Lung Cancer screening technology. This cutting-edge technology can screen a patient for 29 lung diseases in a single chest X-ray, enhancing diagnostic capabilities.

• Government of Goa to accelerate the detection of lung cancer through the deployment of stateof-the-art Artificial Intelligence (AI) based screening technology developed by Qure.ai.

• Roche Diagnostics India, focusing on improving diagnostics for breast cancer patients. The collaboration aims to streamline HER2 diagnostics with the latest advancements in the field.

• Rajiv Gandhi Cancer Institute and Research Center (RGCI&RC) , Delhi to set up a Center of Excellence (CoE) to enhance the availability of subsidized, high-quality, and validated NGS (NextGeneration Sequencing) molecular panel testing for eligible individuals diagnosed with lung cancer in India.

• Inaugurated a dedicated CoEs for severe asthma at Manipal Hospital, Goa; and Brahma Kumaris Hospital, Mumbai . This facility plays a pivotal role in treating and managing severe asthma patients and serves as a guiding force for evolving severe asthma centers.

• Mankind Pharma Limited for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license.

==> picture [96 x 27] intentionally omitted <==

Sustainability & community highlights:

• Launched the global AZ Forest program in India , aiming to plant and maintain an estimated 64 million plants and trees in Meghalaya. Collaborated with Earthbanc, Earthtree, Worldview Impact (India), and Hill Farmers Shiitake Mushroom Coop Society on the 'Meghalaya Reforestation and Sustainable Livelihoods Project' (Regeneration Meghalaya), a 30-year initiative in northeast India.

• Ganga Godavari Cancer Screening Program dedicated to creating cancer awareness and early detection of oral, breast, and cervical cancers among women. We have screened over 10,000 women across 125+ camps in Delhi, Nasik, and Patna through specialized screening camps and community mobilization. Collaborating with state governments, Mohalla Clinics, the National Association for Reproductive and Child Health of India for PNP, and local government hospitals such as Lady Hardinge, Dr. B.R. Ambedkar Hospitals, SMBT Hospital, and Mahavir Cancer Sansthan, we aim to make a significant impact on women's health.

• Young Health Program focused on building knowledge and capacity among young people to limit risk behaviors and promote long-term health, this program has reached over 95,000 youth through 43 community activities. We have trained 145 youth as peer educators and 75 healthcare workers, engaging 28 government stakeholders to ensure a broader impact on youth health education.

Recogni�ons:

• The Economic Times Best Healthcare Brands Award 2023 for growth, excellence and a commitment to innovation in sector

• AsiaOne G20 Healthcare Commitment Award for our commitment to the healthcare and wellbeing

• Avtar Most Inclusive Companies Index (MICI): Best Companies for Women for six consecutive years

• Great Place To Work[® ] Certification™: Recognised for six consecutive years

• Sustainability Initiative Award of the Year for our zero-carbon ambition and industry leading initiatives by UBS Forums

• ESG Champions of India 2024 in Biotechnology & Pharmaceuticals by Dun & Bradstreet India

• Dr. Sanjeev Panchal: Recognized among India’s Impac�ul CEOs by Times Now for outstanding leadership.

• Amarpreet Kaur Ahuja, Country HR Director- India

• Awarded the Diversity & Inclusion HR Leader of the Year 2023 by Ask Insights & TOI, showcasing excellence in fostering diversity and inclusion.

• Featured among the most influen�al woman in HR-2024 by BW People

AstraZeneca India con�nues to make significant strides, demonstra�ng a commitment to innova�on, healthcare advancements, environmental sustainability, and leadership excellence.

About AstraZeneca:

AstraZeneca is a global, science-led biopharmaceu�cal company that focuses on the discovery, development and commercialisa�on of prescrip�on medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Diseases. AstraZeneca operates in over 100 countries and its innova�ve medicines are used by millions of pa�ents worldwide. Established in 1979, it is headquartered at Bengaluru, Karnataka and has a workforce of over 900 employees across the country commi�ed to deliver great medicines to pa�ents through innova�ve science and global excellence in development and commercializa�on. For more informa�on, please visit our website: www.astrazeneca.com/india, or connect with us on LinkedIn and X.com.